Rac Binding to p67phox
STRUCTURAL BASIS FOR INTERACTIONS OF THE Rac1 EFFECTOR REGION AND INSERT REGION WITH COMPONENTS OF THE RESPIRATORY BURST OXIDASE*

(Received for publication, October 28, 1996, and in revised form, May 1, 1997)

Yukio Nisimoto Dagger §, Jennifer L. R. Freeman §par , Shabnam Azar Motalebi , Miriam Hirshberg ** and J. David Lambeth Dagger Dagger

From the  Department of Biochemistry, Emory University Medical School, Atlanta, Georgia 30322, the Dagger  Department of Biochemistry, Aichi Medical University, Nagakute Aichi 480-11, Japan, and the ** National Institute for Medical Research, Mill Hill, London NW7 1AA, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Activation of the respiratory burst oxidase involves the assembly of the membrane-associated flavocytochrome b558 with the cytosolic components p47phox, p67phox, and the small GTPase Rac. Herein, the interaction between Rac and p67phox is explored using functional and physical methods. Mutually facilitated binding (EC50) of Rac1 and p67phox within the NADPH oxidase complex was demonstrated using steady state kinetic methods measuring NADPH-dependent superoxide generation. Direct binding of Rac1 and Rac2 to p67phox was shown using a fluorescent analog of GTP (methylanthraniloyl guanosine-5'-[beta ,gamma -imido]triphosphate) bound to Rac as a reporter group. An increase in the methylanthraniloyl fluorescence was seen with added p67phox but not p47phox, and the emission maximum shifted from 445 to 440 nm. Rac1 and Rac2 bound to p67phox with a 1:1 stoichiometry and with Kd values of 120 and 60 nM, respectively. Mutational studies (Freeman, J., Kreck, M., Uhlinger, D. J., and Lambeth, J. D. (1994) Biochemistry 33, 13431-13435; Freeman, J. L., Abo, A., and Lambeth, J. D. (1996) J. Biol. Chem. 271, 19794-19801) previously identified two regions in Rac1 that are important for activity: the "effector region" (residues 26-45) and the "insert region" (residues 124-135). Proteins mutated in the effector region (Rac1(N26H), Rac1(I33N), and Rac1(D38N)) showed a marked increase in both the Kd and the EC50, indicating that mutations in this region affect activity by inhibiting Rac binding to p67phox. Insert region mutations (Rac1(K132E) and L134R), while showing markedly elevated EC50 values, bound with normal affinity to p67phox. The structure of Rac1 determined by x-ray crystallography reveals that the effector region and the insert region are located in defined sectors on the surface of Rac1. A model is discussed in which the Rac1 effector region binds to p67phox, the C terminus binds to the membrane, and the insert region interacts with a different protein component, possibly cytochrome b558.


INTRODUCTION

Neutrophils and macrophages reduce molecular oxygen with NADPH to produce superoxide (Obardot 2) and secondarily derived reactive oxygen species (H2O2, HOCl, OH·), which function to kill phagocytosed microorganisms (1-4). Superoxide generation is catalyzed by an NADPH oxidase (also called the respiratory burst oxidase), which is dormant in resting cells but becomes active upon exposure to bacteria or to a variety of soluble stimuli. The enzyme consists of both cytosolic and plasma membrane-associated protein factors. Flavocytochrome b558 is a membrane-associated heterodimer (5-7) that contains putative binding sites for NADPH, FAD, and heme (8-11) and therefore represents the enzymatic component of the NADPH oxidase. Three cytosolic components (p47phox, p67phox, and a small molecular weight GTP-binding protein, Rac), activate superoxide generation and can be considered to be regulatory subunits of the flavocytochrome. p47phox, while not essential for activity, functions as a regulated adaptor protein that increases the binding of p67phox to the oxidase 100-fold (12). p47phox appears to act by coupling p67phox to the 22-kDa subunit of the flavocytochrome b558 (13-15). p47phox and p67phox exist in the cytosol of resting cells as a complex along with a third component, p40phox (16, 17), which may function as an inhibitory protein. p47phox and p67phox translocate to the plasma membrane (18-21), and this correlates with cell activation. In a cell-free system, p47phox and p67phox form a 1:1:1 complex with flavocytochrome b558 (22).

The small molecular weight GTP-binding protein, Rac, occurs as two isoforms (Rac1 and Rac2) that are 92% identical in amino acid sequence (23). The two isoforms differ primarily in their C termini; Rac1 but not Rac2 contains a polybasic C terminus. In resting cells, Rac is located in a cytosolic complex with an inhibitory protein, RhoGDI (24-27). Upon cell activation, Rac2, the more abundant isoform in neutrophils (28-30), becomes associated with the plasma membrane (28), and translocation correlates with NADPH oxidase activity (28, 30, 31).1 Translocation of Rac requires neither p47phox nor p67phox and occurs with different kinetics than these other cytosolic components (34-37), suggesting that the binding of Rac to the plasma membrane is regulated by mechanisms that are distinct from those that regulate p47phox/p67phox assembly. In their isoprenylated forms, both Rac1 and Rac2 can activate superoxide generation in a cell-free system (38-40). Kinetic characterization and binding studies are complicated by the presence of the isoprenyl group, which limits the solubility and requires the presence of a detergent. The proteins in their nonisoprenylated forms can be expressed in and purified from bacteria. However, in their nonisoprenylated forms, only Rac1 activates efficiently. This is because membrane association is essential for optimal function of Rac, and nonisoprenylated Rac1 can interacts with the membrane via its polybasic C terminus (41). Bacterially expressed versions of Rac1 have therefore been used for most of the studies described herein.

We have previously characterized two regions on Rac1 that are important for its ability to activate the NADPH oxidase. These are the effector region (within the range of residues 26-45) and the insert region (residues 124-135). The effector region shows homology to a region on Ras that has been characterized as mediating the GTP-dependent binding to the Ras effector Raf-1, a member of the MAP kinase cascade (42, 43). The effector region of Ras includes residues the conformation of which changes significantly depending on whether GTP or GDP is bound. The insert region on Rac has no counterpart in Ras. Mutation of residues in both the effector region and the insert region of Rac1 results in a marked decrease in the ability to support cell-free superoxide generation (44-46), and the primary effect was decreased affinity of Rac1, based upon an increase in the EC50 (44, 47).

Rac1 has been shown to bind to immobilized p67phox (48, 49), and the interaction has been demonstrated using yeast two-hybrid analysis, but it is not clear whether Rac also interacts with other targets. In addition, no quantitative information on Rac binding to p67phox is available (e.g. affinity, stoichiometry). Herein, steady state kinetic analysis was used to demonstrate the functional linkage between Rac and p67phox. In addition, Rac binding to p67phox was measured directly, making use of a fluorescent GTP analog that binds tightly to Rac as a reporter group. The Rac-associated analog undergoes an increase in fluorescence upon interaction of Rac with p67phox, and this fluorescence change was used to quantify the Rac binding to p67phox. This method, used in conjunction with mutational analysis, reveals that the effector region participates in binding to p67phox, while the insert region does not. Mapping of residues the mutation of which lowers activity onto the structure of Rac1 (recently determined by x-ray crystallography; Ref. 50) reveals that the effector region and the insert region are located in distinct sectors of the protein, consistent with a model in which these two regions bind to distinct targets within the NADPH oxidase complex.


EXPERIMENTAL PROCEDURES

Materials

Cytochrome c (type VI), NADPH, n-octyl glucoside, diisopropyl fluorophosphate, phenylmethylsulfonyl fluoride, and N-alpha -tosyl-L-lysine chloromethylketone were from Sigma. GTPgamma S was purchased from Boehringer Mannheim. HESPAN (6% hetastarch in 0.9% NaCl) was from American Hospital Supply Corp., and lymphocyte separation medium (6.2% Ficoll, 9.4% sodium diatrizoate) was obtained from Organon Tekniker. Superoxide dismutase and dithiothreitol were from Wako Pure Chemical Co. Heparin-Sepharose CL-6B, DEAE-Sepharose CL-6B, CM-Sepharose CL-6B, omega -aminooctyl-agarose, and glutathione-Sepharose were purchased from Pharmacia LKB. L-alpha -phosphatidylcholine (bovine brain), L-alpha -phosphatidylethanolamine (bovine brain), L-alpha -phosphatidylinositol (bovine brain), and sphingomyelin (bovine erythrocyte) were from Sigma. All other reagents were of the highest grade available commercially. Methyl isotoic anhydride was purchased from Molecular Probes (Eugene, OR), and mant-GppNHp2 was synthesized as described previously (51).

Preparation of Recombinant Proteins

Recombinant p67phox was expressed and purified from baculovirus-infected Hi5 insect cells as described (22, 31). Wild type and mutant Rac1 were expressed in Escherichia coli as the glutathione S-transferase fusion proteins, purified using glutathione-Sepharose beads, and cleaved from the glutathione S-transferase domain with thrombin (52). All recombinant proteins were purified to greater than 95% homogeneity.

Isolation of Human Neutrophils and Plasma Membrane Preparation

Human neutrophils were obtained from peripheral blood of normal healthy donors after obtaining informed consent. Erythrocytes were sedimented with HESPAN, and the mononuclear cells were removed from the resulting supernatant by centrifugation through lymphocyte separation medium (53). The resulting cells were greater than 95% neutrophilic granulocytes. Neutrophils were resuspended in cavitation buffer (25 mM HEPES, pH 7.4, containing 100 mM KCl, 3 mM NaCl, 5 mM MgCl2, 6 µM diisopropyl fluorophosphate, 0.5 mM phenylmethylsulfonyl fluoride, 2 µM each leupeptin, pepstatin, and aprotinin). Cells (6 × 109) in 20 ml of ice-cold buffer were disrupted by nitrogen cavitation after being pressurized at 500 p.s.i. for 20 min at 4 °C, and plasma membranes were prepared as described (54).

Purification and Reconstitution of Flavin-depleted Cytochrome b558 with FAD

Plasma membrane was solubilized in the presence of 40 mM octyl glucoside and 0.5% sodium cholate (11). Detergent-solubilized cytochrome b558 was purified as described previously (9) with some modifications (11). Purified FAD-depleted cytochrome b558 (15.6 nmol of heme/mg of protein) was incubated in 50 mM Tris acetate buffer, pH 7.45, containing 5 mM KCl, 10% glycerol, 1 mM dithiothreitol, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 2 µM each leupeptin, pepstatin, and aprotinin (buffer B), and phospholipids (L-alpha -phosphatidylcholine/L-alpha -phosphatidylethanolamine/L-alpha -phosphatidylinositol/sphingomyelin/cholesterol = 4:2:1:3:3 (w/w/w/w/w); lipid/protein = 100, w/w) were added along with a 10-fold excess of FAD over heme. After incubating at 4 °C for 2 h, the mixture was dialyzed against two changes of buffer B to remove free FAD. The FAD-reconstituted material typically contained a FAD:heme ratio of 0.4-0.5 (11).

Spectrophotometric Assay

The heme content of cytochrome b558 reconstituted with FAD and phospholipids was determined by reduced minus oxidized difference spectroscopy at 424-440 nm using an extinction coefficient of 161 mM-1·cm-1 (55). The flavin content of FAD-reconstituted cytochrome b558 was estimated by the fluorimetric method (11). Fluorescence spectra were recorded with a Hitachi model F-3000 spectrofluorimeter, and routine fluorescence measurements were made with a Perkin-Elmer LS-5B spectrofluorimeter. Samples (mant-GppNHp, Rac 1, cytochrome b558, and cytosolic factors) were incubated at 20 °C in 0.3 ml of 20 mM Tris acetate buffer, pH 7.45, containing 3 mM NaCl, 50 mM KCl, and 0.1 µM MgCl2. Preloading of Racs with mant-GppNHp was carried out for 15-20 min, at which point the fluorescence change due to the guanine nucleotide binding was stable. Low MgCl2 concentration was essential to facilitate complete guanine nucleotide exchange. Titrations were carried out by adding p67phox and recording fluorescence readings until three successive stable readings, at least 45 s apart, were obtained. Fluorescence changes induced by p67phox occurred rapidly (within 1-2 min) and did not change further with prolonged incubation. Spectral resolution was 5 nm for both the excitation and emission paths, respectively.

Assay of Cell-free Superoxide Generation

Superoxide generation was measured by superoxide dismutase-inhibitable reduction of cytochrome c as described previously (54) using a Thermomax kinetic microplate reader (Molecular Devices, Menlo Park, CA). Rac, preloaded with a 5-fold molar excess of GTPgamma S for 15 min at 25 °C in the absence of MgCl2 (52), was combined with p47phox, p67phox, 10 nM cytochrome b558, and 1 µM FAD followed by activation with 40 µM arachidonate in 50 mM NaCl, 4 mM MgCl2, 1.25 mM EGTA, 20 mM Tris-HCl, pH 7.0, as described (56). The mixture was incubated at 25 °C for 5 min followed by the addition of 200 µM NADPH and 200 µM cytochrome c. An extinction coefficient at 550 nm of 21 mM-1 cm-1 was used to calculate the quantity of cytochrome c reduced (57).

Data Fitting and Calculation of Kd Values

The theoretical lines through the data shown in Figs. 1 and 2 were calculated using a nonlinear least squares fit of the data using the Michaelis-Menten equation and were plotted using Sigma Plot. Kinetic constants are reported as Vmax and EC50 (effective concentration at 50% of Vmax). Fluorescence titrations were fit to a single site binding equation as described previously (58) as follows,
&Dgr;F=&Dgr;F<SUB><UP>max</UP></SUB>((K<SUB>d</SUB>+L<SUB>T</SUB>+R<SUB>T</SUB>)−((K<SUB>d</SUB>+L<SUB>T</SUB>+R<SUB>T</SUB>)<SUP>2</SUP>−4 L<SUB>T</SUB>R<SUB>T</SUB>)<SUP>1/2</SUP>/2R<SUB>T</SUB>) (Eq. 1)
where Delta F is the fluorescence change after each addition of p67phox, Delta Fmax is the maximal fluorescence change at infinite (extrapolated) p67phox, Kd is the dissociation constant, LT is the concentration of p67phox, and RT is the total concentration of Rac(mant-GppNHp). Sigma plot was used to generate a nonlinear least squares fit of the data, solving for Kd and Delta Fmax, constraining the fit to the actual concentration of Rac(mant-GppNHp) used in the experiment. For the Rac(D38N) mutation, it was necessary to assume the Delta Fmax to be the same as that of the wild type, since binding was weak and it was not feasible to approach saturation.


Fig. 1. Mutually facilitated effects of Rac1 and p67phox on EC50 values in the cell-free NADPH oxidase system. A, data are plotted in Lineweaver-Burk format. Each point represents the average of at least three determinations. The concentration of Rac was varied as indicated in the presence of 3 µM p67phox (triangles), 1.5 µM p67phox (filled circles), or 0.5 µM p67phox (open circles) and 10 nM cytochrome b558, which had been reconstituted with FAD and phospholipid. p47phox was not present in the incubation. Superoxide generation was quantified by cytochrome c reduction, as described under "Experimental Procedures." B, the concentration of p67phox was varied as indicated in the presence of 2 µM Rac (triangles), 0.5 µM Rac (filled circles), or 0.2 µM Rac (open circles), and the assay for superoxide generation was carried out as in A.
[View Larger Version of this Image (14K GIF file)]


Fig. 2. Comparison of mant-GppNHp and GTPgamma S in the activation of superoxide generation by Rac1 and point-mutated Rac1. An aliquot of cytochrome b558 (10 nM final concentration) reconstituted with phospholipid and FAD was preincubated at 25 °C with 0.25 mM arachidonate, recombinant p47phox (0.2 µM), p67phox (0.1 µM), and Rac or the indicated point-mutated Rac (0.5 µM), which had been "preloaded" with either GTPgamma S (solid bars) or mant-GppNHp (hatched bars). W.T., wild type Rac1; N26H, Rac1(N26H); D38N, Rac1(D38N). Superoxide generation was assayed as described under "Experimental Procedures." The average and S.E. of a minimum of three determinations are shown.
[View Larger Version of this Image (24K GIF file)]


RESULTS

Mutually Facilitated Binding of Rac and p67phox in the NADPH Oxidase Complex, Demonstrated by Steady State Kinetics

We previously showed that a functional interaction between p67phox and p47phox, which are known to form a complex, can be demonstrated using steady state kinetics assaying superoxide generation; in the presence of the other required components, the EC50 for each protein was found to vary inversely with the concentration of the partner protein (59). This result indicates a thermodynamic linkage between the binding of the two proteins within the NADPH oxidase complex and is consistent with a complex between the partner proteins. This approach was tried with p67phox and Rac1 under conventional assay conditions (in the presence of p47phox), but effects of varying the concentration of one protein on the EC50 of the other protein were not seen. We attribute this to the already high affinity of both components in the oxidase complex, which makes it difficult to observe further decreases in their EC50 values, and to the presence of multiple binding interactions for each of the proteins, which may obscure observation of such interactions. However, the system can be simplified, since p47phox need not be present to observe high activity when high concentrations of p67phox and Rac1 are used (12). The omission of p47phox simplifies the kinetic analysis; the 50-100-fold weaker binding of Rac1 and p67phox makes any decreases in EC50 values easy to detect, and p47phox is ruled out as a mediator of any observed kinetic linkage that must therefore be due to direct interactions among the remaining components (Rac1, p67phox, cytochrome b558). Under these conditions, the EC50 for Rac1 decreased at increasing concentrations of p67phox (Fig. 1A). Likewise, at increasing concentrations of Rac1, the EC50 for p67phox decreased (Fig. 1B). A 6-fold increase in the concentration of p67phox resulted in a roughly 5-fold decrease in the EC50 for Rac, while a 10-fold increase in Rac concentration resulted in a >2-fold decrease in the EC50 for p67phox. These data imply a functional interaction between p67phox and Rac1, consistent with a complex between these two proteins.

Characterization of the Binding of Mant-GppNHp, a Fluorescent Derivative of GTP, to Rac1

We previously showed that mant-GppNHp binding to Rac1 is accompanied by an increase in fluorescence at 445 nm, the emission peak of the mant moiety, and we have used this increased fluorescence to quantify the binding of mant-GppNHp to Rac1 and point-mutated types of Rac1 (47). We used this fluorescence increase in the present studies to verify that Rac1, Rac2, Rac1(N26H), Rac1(I33N), Rac1(D38N), Rac1(M45T), Rac1(K132E), and Rac1(L134R) all bind mant-GppNHp tightly and achieve maximal binding within the same time period. Quantifying binding as described previously, all of these recombinant forms of Rac bound the guanine nucleotide with an approximate 1:1 stoichiometry and with apparent Kd values in the 1-20 nM range. In addition, all had achieved maximal fluorescence change by about 5 min, well within the 15-20 min incubation period used for preloading of Rac1 with the nucleotide. Examination of the Rac1 structure (50) shows that the side chains of these mutants do not directly interact with the nucleotide, are relatively exposed, and can accommodate the respective mutations without altering the overall fold of the protein. As a control, Rac(T17N), a mutation that in Ras renders this GTPase incapable of binding guanine nucleotide, did not produce any fluorescence change when added to mant-GppNHp. Thus, by preincubating mant-GppNHp in the presence of a slight excess of Rac or Rac mutants, a fully associated complex between the fluorescent nucleotide and Rac was formed. The ability of mant-GppNHp to produce an active conformation of representative versions of Rac1 was also investigated. Mant-GppNHp was compared with GTPgamma S (0.5 µM each) in their abilities to support NADPH-dependent superoxide generation, using purified oxidase components in the cell-free system. Using wild type Rac1 (Fig. 2), the mant-GppNHp supported superoxide generation to about 60% of the level seen with GTPgamma S. For representative point-mutated forms (Rac1(N26H) and Rac1(D38N)) that have a reduced ability to stimulate superoxide generation (44), the mantGppNHp worked nearly as well as GTPgamma S.

Effects of NADPH Oxidase Components on the Fluorescence of Mant-GppNHp

Fig. 3A (solid line) shows the emission spectrum for mant-GppNHp free in solution. Upon addition of Rac1, there was a small increase in fluorescence (about 5%), as was described previously (dotted line). When p67phox was added, there was a further increase in the mant fluorescence, and the emission maximum was blue-shifted about 5 nm (Fig. 3A, dashed line). This was not due to any direct effect of p67phox on the free mant-GppNHp, since p67phox had no effect on its fluorescence in the absence of Rac1 (Fig. 3C). In Fig. 3B, p47phox was added to the mant-GppNHp·Rac complex. In contrast to p67phox, there was no increase in the fluorescence intensity upon the addition of p47phox (compare solid and superimposed dotted lines). When both p47phox and p67phox were added to the Rac(mant-GppNHp) complex (dashed line), the fluorescence increase was essentially the same as that produced by p67phox alone. Furthermore, the addition of 0.25 mM arachidonate caused no significant effect on the fluorescence enhancement due to the binding of p67phox to Rac(mant-GppNHp), indicating that the guanine nucleotide-dependent binding of Rac1 to p67phox occurs whether or not arachidonate is present.


Fig. 3. Effect of p67phox on the fluorescence of the mant-GppNHp·Rac complex. A, the solid line shows the fluorescence emission spectrum (excitation wavelength, 355 nm) of mant-GppNHp (0.12 µM) in 20 mM Tris-HCl buffer, pH 7.45, containing 3 mM NaCl, 50 mM KCl, and 0.1 µM MgCl2 (solid line). After adding 0.25 µM Rac 1 and incubating for 20 min at 20 °C, the fluorescence spectrum was recorded (dotted line, middle spectrum). Fifteen minutes after the addition of 0.30 µM p67phox the emission spectrum (broken line, upper spectrum) was recorded. B, after recording a spectrum of the Rac(mant-GppNHp) complex (solid line), 0.30 µM p47phox was incubated with the mixture for 20 min, and then the spectrum (dotted line, no change from solid line) was recorded. p67phox (0.30 µM) was then added, and the emission spectrum (broken line) was recorded as above. C, the solid line shows the emission spectrum of mant-GppNHp (0.12 µM) in the absence of added Rac1. The superimposed dotted line shows the spectrum 20 min after the addition of p67phox (0.3 µM), again in the absence of Rac1.
[View Larger Version of this Image (15K GIF file)]

The increase in fluorescence of Rac(mant-GppNHp) was used to quantify the strength of binding of Rac to p67phox. Fig. 4 shows the titration of Rac1(mant-GppNHp) with p67phox and p47phox. As above, p47phox had no effect on the fluorescence of Rac(mant-GppNHp), while p67phox produced a saturable increase in the fluorescence. The increase in fluorescence fit a theoretical curve (Fig. 4, solid line) for single site binding of p67phox to Rac (i.e. no cooperativity was detected). In the experiment shown, the apparent binding constant was 170 nM, somewhat weaker than published values for the EC50 (<= 50 nM) for Rac in cell-free superoxide generation assays (47). The average of 11 such titrations gave an value of 124 ± 15 nM, as summarized in Table I. The binding experiment was also carried out in the presence of p47phox (see Table I, titration not shown). p47phox did not affect the ability of Rac1 to bind to p67phox. In addition, the binding experiment was also carried out in the presence of arachidonate. Although this did not appear to affect binding in a significant way, increased light scattering prevented detailed quantitative analysis and did not permit us to carry out binding and activity experiments under identical conditions.


Fig. 4. Quantitation of p67phox binding to Rac1 using the increase in fluorescence of mant-GppNHp bound to Rac1. Rac1 (1.2 µM) was preincubated with 0.85 µM mant-GppNHp for 15-20 min as above to form the Rac·mant-GppNHp complex. This was then titrated with either p67phox (filled circles) or p47phox (filled triangles), and the fluorescence was recorded after each addition (excitation and emission wavelengths were 355 and 440 nm, respectively) until a stable value was achieved (about 3 min). The increase in fluorescence intensity is shown as a function of the concentration of the added component. The observed fluorescence was corrected for volume changes. The line shown is a theoretical fit of the data, calculated as described under "Experimental Procedures." The Kd value describing the theoretical line is 0.17 µM.
[View Larger Version of this Image (18K GIF file)]

Table I. Comparison of binding affinity of native and point-mutated forms of Rac(Mant-GppNHp) for p67phox with kinetically determined EC50 values for Rac activation of superoxide generation

Kd values were obtained as described under "Experimental Procedures" using data from experiments such as those shown in Figs. 3, 4, and 5. EC50 values were obtained as described previously (44) in experiments using recombinant p47phox, p67phox, and Rac (or Rac mutants) along with plasma membrane as a source of cytochrome b558, using Michaelis-Menten steady state kinetic analysis of superoxide generation, which was quantified using cytochrome c reduction as in Fig. 1. The tabulated values show the average ± S.E. of the mean or range, and the number in parenthesis indicates the number of independent experiments used to calculate the averages.

Rac isoform or mutant Kd EC50

nM
Rac1 124  ± 15 (10) <50a
Rac2 61  ± 26 (2) 1,300b
Rac1 (N26H) 800  ± 230 (4) 2,700  ± 1,000 (3)
Rac1 (I33N) 3,900  ± 700 (5) 2,400  ± 1,600 (2)
Rac1 (D38N) 5,100  ± 920 (6) 4,600  ± 400 (3)
Rac1 (M45T) 230  ± 20 (3) 2,500  ± 1,400 (3)
Rac1 (K132E) 90  ± 20 (4) 1,500  ± 500 (3)
Rac1 (L134R) 100  ± 10 (4) 1,350  ± 850 (3)
Rac/Rho chimera >20,000 No activity
Rac1 + p47 140  ± 30 (2)

a Reported by Freeman et al. (47) as an upper limit value.
b Reported by Kreck et al. (41).

Comparison of the Binding of Rac1, Rac2, and Mutants of Rac1 to p67phox

Titrations of mant-GppNHp complexes of Rac1 and Rac2 with p67phox are shown in Fig. 5. Binding of p67phox to Rac2(mant-GppNHp) gave a somewhat smaller maximal fluorescence yield, but the calculated Kd value was 2-fold lower than that using Rac1(mant-GppNHp), as summarized in Table I. This slightly higher affinity of Rac2 is consistent with studies using the yeast two-hybrid system to detect the interaction of Rac1 and Rac2 with p67phox (49). While quantitation is not possible using this method, the use of the Rac2 hybrid yielded a more intense blue color in the two-hybrid assay, suggesting enhanced binding. In contrast to the increased binding of Rac2 to p67phox, the EC50 for Rac2 was markedly elevated compared with Rac1 in the cell-free NADPH-superoxide generation assay (Table I).


Fig. 5. Comparison of binding of Rac1, Rac2, and Rac1 point mutants to p67phox. Titrations were carried out as in Fig. 4. The concentration of Rac or Rac mutants in various experiments shown ranged from 0.25 to 0.6 µM, and the corresponding concentration of mant-GppNHp was 70% of the Rac concentration. The Rac form used is indicated in each panel. The lines shown are derived from theoretical fits of the data, as described under "Experimental Procedures." The arrowheads on the y axes indicate the maximal fluorescence change, which was obtained either by extrapolation according to Equation 1 (top panels and lower right panel) or in a parallel titration using Rac1 (remaining panels) in cases where an accurate Delta Fmax could not be obtained by extrapolation. Kd values obtained in these and other titrations are shown in Table I.
[View Larger Version of this Image (23K GIF file)]

Point mutations of Rac1 were previously characterized (44) and shown to produce large changes in the EC50 for Rac1 in the cell-free NADPH-superoxide generation assay. Previous published values as well as unpublished experiments were averaged to obtain the EC50 values (Table I). The binding of these mutated Rac1 forms was quantified using mant fluorescence as above. Results are shown in Fig. 5, and averages of Kd values obtained in several independent experiments are summarized in Table I. Representative mutations in both the effector region and the insert region were investigated. While native Rac1 bound tightly to p67phox, mutations in the effector region weakened the binding. In particular, the mutations at the 33- and 38-positions showed large effects on binding, while those at the more extreme ends of the effector region (positions 26 and 45) produced smaller but reproducible effects. Thus, decreased binding to p67phox accounts for the decreased ability of effector region mutants to support superoxide generation. In contrast, mutations in the insert region of Rac1 produced large effects on the EC50 for superoxide generation in the cell-free system but showed no effect on the Kd for Rac1 binding to p67phox. Thus, Rac1 does not appear to utilize its insert region to bind to p67phox.

Finally, an additional region on Rac C-terminal to residue 143 for interaction with p67phox has been postulated, based on the inability of a Rac143Rho chimera (N-terminal 143 residues from Rac1, with the rest from RhoA) to bind to p67phox using overlay blotting methods (60). Using this chimera, we confirmed that the chimera was inactive in supporting superoxide generation and that it failed to bind significantly to p67phox (Table I).


DISCUSSION

Binding of Rac1 to p67phox

Direct demonstration of a stoichiometric complex between Rac1 and p67phox has proven to be difficult, presumably due to the kinetic and or thermodynamic lability of the complex. We previously attempted to demonstrate interaction using gel filtration but were unable to detect a stable complex.3 Binding of Rac isoforms to p67phox has been demonstrated using p67phox (or a p67phox-GST fusion protein) immobilized on glutathione beads (46) or on a nitrocellulose filter (48, 60) and also by yeast two-hybrid analysis (49). However, a large excess of Rac was used in the first two cases, and the percentage of binding was low compared with that predicted for a 1:1 complex. Using both methods, effector region mutations disrupted the interactions, suggesting that the Rac-p67phox binding is relevant to regulation of the NADPH oxidase. While informative, neither of these methods is quantitative, and neither can be used to obtain direct measures of binding affinity or stoichiometry. In the present studies, a fluorescent derivative of GTP has proven to be effective for this purpose. The mant is bound through the 3'-hydroxyl group of the ribose ring. O3' is exposed to solvent, making only a weak hydrogen bond with E31 (50). The mant-GppNHp should bind to Rac1 without altering the basic interactions between the nucleotide and the protein, thus serving as a good reporter for binding. The quantum yields of mant guanine nucleotides shows high sensitivity to solvent polarity and to small changes in protein environment (51), and mant-modified nucleotides have been used to demonstrate both binding of nucleotides to their binding proteins (47, 63, 64) and the interaction of the guanine nucleotide-protein complex with a second protein (58). In the latter study, the complex between RhoGDI and Cdc42Hs has been demonstrated, based on quenching of the fluorescence of the Cdc42Hs(mant-GDP) complex upon interaction with RhoGDI.

A requirement for the use of this method is that the fluorescent group must bind tightly to one of the interacting proteins and that it should induce an active conformation of the protein. The complex between mant-GppNHp and Rac1 was therefore initially characterized. As is shown in Fig. 3, complex formation was accompanied by a small increase in the fluorescence of the mant moiety. As was shown previously, this fluorescence change was used to quantify the binding of mant-GppNHp to Rac1 (47). In agreement with earlier studies, the complexes show high affinity, with apparent Kd values ranging from 1 to 20 nM for native and point mutated forms of Rac. Mutant forms of Rac showing elevated Kd values for guanine nucleotide binding (including Rac1(A59T) and Rac1(T75K)) were eliminated from consideration in this study. The mant-GppNHp generates an active conformation of Rac1, albeit somewhat less active than that produced by GTPgamma S. We presume that the binding affinities generally reflect those that occur in the active complex with nonfluorescent nucleotide, but it is possible that these are perturbed in subtle ways due to the presence of the fluorescent group.

Using the fluorescence method we find that Rac(mantGppNHp) binds to p67phox with a Kd of 110 nM. While this is a moderately high affinity, it is considerably weaker than the binding of many signaling complexes, perhaps accounting for the instability of this complex to gel filtration chromatography and the low stoichiometry of binding found using other methods. The EC50 for Rac1 in activating superoxide generation is <= 60 nM (the actual EC50 is probably less, since this represents an upper limit value; see Ref. 47). The most likely explanation for the lower value for the EC50 is that other binding interactions in addition to p67phox participate in Rac binding within the NADPH oxidase complex.

Structural Considerations and Rationale for the Effects of Point Mutations on Binding and Activity

Table II lists most of the point mutations that have been characterized either in our own laboratory or in those of other labs and depicts effects on activity and on binding to p67phox. Because the methodologies used and the expression of data are not directly comparable, the relative activity is indicated by addition symbols (+), with ++++ representing normal activity, and binding is summarized as either "normal" or "weak." Inspection of Table II reveals two regions, the effector region and the insert region, that have large effects on activity and reveals additional regions (e.g. residues in the range of residues 61-105) that have small or no effects. The effector region has been studied extensively by several groups, and a large number of mutations have been made. Except for conservative replacements (e.g. Rac1(I33V)), most changes in this region have large effects on the ability of Rac1 and Rac2 to activate cell-free superoxide generation. The structure of Rac1-GppNHp was recently determined by x-ray crystallography (50) and is shown in Fig. 6A, with the guanine nucleotide indicated in violet. The overall fold of the protein is very similar to that of Ras except for two regions. The insert region, which forms a well defined, exposed, helical domain, and residues 28-38, which are very flexible and are less defined in the x-ray structure (see Ref. 50 for a discussion of these two regions). Effector region mutations summarized in Table II are indicated in maroon, and insert region mutations are in green. As shown in Fig. 6B, the effector region and the insert region represent distinct regions on Rac1. Each can be envisioned as forming a surface for interaction of partner proteins within the NADPH oxidase complex. Except for position 45, which is slightly more distant, all of the effector region mutations cluster closely to form a single surface. Other possible exceptions within the effector region may include threonine 35, which coordinates the magnesium, which is involved in guanine nucleotide binding (50). Other residues within this region are exposed on the surface as part of the effector loop, and mutations of these residues are unlikely to produce a long range effect on the structure of Rac1. Representative mutations (indicated by stars in Fig. 6A) within this region were investigated for their effects on binding to p67phox. These mutations resulted in effects, some quite large, on binding to p67phox. All effector region mutations also affected the EC50 for Rac1 in the cell-free assay. Quantitatively, the magnitude of the effects on binding paralleled the effects on the EC50 for mutations at residues 33 and 38, but the effects on binding were smaller than the effects on EC50 for mutations at positions 26 and 45. This may indicate that the presence of other protein component within the NADPH oxidase complex perturbs the binding of Rac1 to p67phox, particularly at the periphery of the effector region, or that the different assay conditions perturbed the binding energies. The fact that all of the mutations produced effects on both activity and binding argues strongly that the effector region is utilized within the NADPH oxidase complex for binding to p67phox.4

Table II. Summary of effects of point mutations on binding of Rac to p67phox

Since numbers reported for activities in various studies are not directly comparable and since overlay blots could not be quantified in published studies, relative ability to activate is indicated by +, and binding to p67phox is indicated as either "normal" or "weak." WT indicates wild type. Mutant proteins based on Rac2 were expressed in insect cells and were presumably at least partially isoprenylated, whereas all other mutant proteins were expressed in E. coli.

Rac Activity Binding to p67phox Reference

Rac1 (WT) ++++ Normal 44
Rac1 (N26H) + Weak 44 and present study
Rac1 (A27K) + NDa 66
Rac2 (F28L) + ND 45
Rac1 (G30S) + ND 66
Rac1 (I33N) + Weak 44 and present study
Rac1 (I33V) ++++ ND 66
Rac1 (T35A) + Weak 46
Rac2 (T35A) + ND 49
Rac2 (V36R) +++ ND 45
Rac1 (D38N) + Weak 44 and present study
Rac1 (D38A) + Weak 46
Rac2 (D38A) + ND 45
Rac1 (Y40K) + Weak 46
Rac1 (M45T) + Weak 44 and present study
Rac1 (Q61H)b ++ ND c
Rac2 (A61L)b ++++ ND 45
Rac1 (Y64F) +++ ND c
Rac1 (D65N) +++ ND c
Rac1 (V85E) +++ ND c
Rac1 (R102E) ++++ ND d
Rac1 (H104A) ++++ ND d
Rac1 (H105A) ++++ ND d
Rac1 (E127Q) + ND 47
Rac1 (K130N) + ND 47
Rac1 (K132E) + Normal 47 and present study
Rac1 (L134R) + Normal 47 and present study
Rac1 (T135N) + ND 47

a ND, not determined.
b Inhibits GTPase activity.
c J. Freeman and J. Lambeth, unpublished results.
d M. Kreck and J. Lambeth, unpublished results.


Fig. 6. Structural considerations for effector and insert region mutations. A, ribbon diagram indication of mutations in Rac1 affecting cell-free NADPH oxidase activity (taken from Table I). Residues the mutation of which affects activity are indicated, with effector region mutations in brown and insert region mutations in green. Representative mutations were tested for their ability to bind to p67phox. Mutations that weaken the binding of p67phox to Rac (present studies) are indicated by a star, while mutations that failed to affect binding to p67phox are indicated by a filled circle. Residues that are not indicated by either symbol were not investigated in the present studies in the binding assay. B, the structure has been rotated approximately 90 degrees counterclockwise around a vertical axis compared with A. The CPK diagram shows effector loop residues in brown (residues 26-40) and insert region residues (124-135) in green. Residue 45 was omitted in this representation because of its relatively small effect on binding to p67phox. Residue 181 (the last C terminus residue that can be seen in the x-ray structure) is also indicated as C-Terminus. The GppNHp is shown in violet, with the phosphate-containing region shown in a lighter shade.
[View Larger Version of this Image (36K GIF file)]

In contrast to the effector region, representative activity-affecting mutations in the insert region (K132E and L134R in Fig. 6A) had no effect on the binding to p67phox. These residues are largely exposed on the surface of the insert region, and mutations are unlikely to produce structural perturbations outside of the effector region. In addition, the mutated residues do not directly contact the guanine nucleotide, consistent with a lack of effect on guanine nucleotide binding or hydrolysis. Thus, the most likely explanation for the effects of insert region mutations on the EC50 for Rac1 is that these residues participate in binding to another component within the NADPH oxidase complex. We have previously shown that the association of the polybasic C terminus of (nonisoprenylated) Rac1 with the membrane is essential for optimal activity and that this does not occur with nonisoprenylated Rac2 (41). The insert region lies at the opposite pole from the C terminus (Fig. 6B), making unlikely that both regions interact with the membrane. Thus, the data are most consistent with the insert region interacting with a distinct protein component of the NADPH oxidase rather than with the membrane. Since insert region mutations reduce relative activity regardless of whether p47phox is present (data not shown), we speculate that the insert region binds directly to cytochrome b558. We propose a model in which a minimum of three interaction regions on Rac are important for reconstituting cell-free NADPH oxidase activity. The C terminus anchors the Rac to the membrane, while the effector region and the insert region bind, respectively, to p67phox and to another component of the oxidase, possibly cytochrome b558.


FOOTNOTES

*   Supported by National Institutes of Health Grant AI22809.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   The first two authors contributed equally to this study.
par    Present address: Duke Medical Center, Box 3821, Durham, NC 27710.
Dagger Dagger    To whom correspondence should be addressed.
1   However, two studies (32, 33) have concluded that activation fails to correlate with translocation.
2   The abbreviations used are: mant-GppNHp, methylanthraniloyl guanosine-5'-[beta ,gamma -imido] triphosphate; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; mant, methylanthraniloyl.
3   D. J. Uhlinger and J. D. Lambeth, unpublished data.
4   It is not clear from the Rac structure whether the poor binding of p67phox by the Rac143Rho chimera reflects an additional binding surface for p67phox within the 143-175 range. A peptide within this range centered around 163-169 is inhibitory (65), but its mechanism of inhibition has not been reported. In addition, this region contains relatively buried alpha -helix, and it is difficult to envision this helix acting as a binding surface. Much of the 143-175 range also is buried and provides a structural foundation for part of the effector loop. This region differs in 20 of 33 residues between Rac1 and RhoA, and it seems possible that such changes may perturb binding indirectly via effects on the Rac effector loop. Thus, while it is conceivable that this region contains an additional binding site, an indirect effect cannot be ruled out.

ACKNOWLEDGEMENTS

We thank Alan Hall for providing the construct for the Rac143Rho chimera.


REFERENCES

  1. Badwey, J. A., and Karnovsky, M. L. (1980) Annu. Rev. Biochem. 49, 695-726 [CrossRef][Medline] [Order article via Infotrieve]
  2. Chanock, S., El Benna, J., Smith, R., and Babior, B. (1994) J. Biol. Chem. 269, 24519-24522 [Free Full Text]
  3. Segal, A. W., and Abo, A. (1993) Trends Biochem. Sci. 18, 43-47 [CrossRef][Medline] [Order article via Infotrieve]
  4. Clark, R. A. (1990) J. Infect. Dis. 161, 1140-1147 [Medline] [Order article via Infotrieve]
  5. Segal, A. W. (1987) Nature 326, 88-91 [CrossRef][Medline] [Order article via Infotrieve]
  6. Nakamura, M., Sendo, S., van Zwieten, R., Koga, T., Roos, D., and Kanegasaki, S. (1988) Blood 72, 1550-1552 [Abstract]
  7. Parkos, C. A., Dinauer, M. C., Walker, L. E., Rodger, A. A., Jesaitis, A. J., and Orkin, S. H. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 3319-3323 [Abstract]
  8. Rotrosen, D., Yeung, C. L., Leto, T. L., Malech, H. L., and Kwong, C. H. (1992) Science 256, 1459-1462 [Medline] [Order article via Infotrieve]
  9. Segal, A. W., West, I., Wientjes, F., Nugent, J. H. A., Chavan, A. J., Haley, B., Garcia, R. C., Rosen, H., and Scrace, G. (1992) Biochem. J. 284, 781-788 [Medline] [Order article via Infotrieve]
  10. Sumimoto, H., Sakamoto, N., Nozaki, M., Sakaki, Y., Takeshige, K., and Minakami, S. (1992) Biochem. Biophys. Res. Commun. 186, 1368-1375 [Medline] [Order article via Infotrieve]
  11. Nishimoto, Y., Otsuka-Murakami, H., and Lambeth, D. (1995) J. Biol. Chem. 270, 16428-16434 [Abstract/Free Full Text]
  12. Freeman, J. L., and Lambeth, J. D. (1996) J. Biol. Chem. 271, 22578-22582 [Abstract/Free Full Text]
  13. de Mendez, I., Garrett, M. C., Adams, A. G., and Leto, T. (1994) J. Biol. Chem. 269, 16326-16332 [Abstract/Free Full Text]
  14. Sumimoto, H., Kage, Y., Nunoi, H., Sasaki, H., Nose, T., Fukumaki, Y., Ohno, M., Minakami, S., and Takeshige, K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5345-5349 [Abstract]
  15. De Leo, F., Ulman, K., Davis, A., Jutila, K., and Quinn, M. (1996) J. Biol. Chem. 271, 17013-17020 [Abstract/Free Full Text]
  16. Someya, A., Nagaoka, I., and Yamashita, T. (1993) FEBS Lett. 330, 215-218 [CrossRef][Medline] [Order article via Infotrieve]
  17. Wientjes, F. B., Hsuan, J. J., Totty, N. F., and Segal, A. W. (1993) Biochem. J. 296, 557-561 [Medline] [Order article via Infotrieve]
  18. Heyworth, P. G., Curnutte, J. T., Nauseef, W. M., Volpp, B. D., Pearson, D. W., Rosen, H., and Clark, R. A. (1991) J. Clin. Invest. 87, 352-356 [Medline] [Order article via Infotrieve]
  19. Lomax, K. J., Leto, T. L., Nunoi, H., Gallin, J. I., and Malech, H. L. (1989) Science 245, 409-412 [Medline] [Order article via Infotrieve]
  20. Leto, T. L., Lomax, K. J., Volpp, B. D., Nunoi, H., Sechler, J. M. G., Nauseef, W. M., Clark, R. A., Gallin, J. I., and Malech, H. L. (1990) Science 248, 727-730 [Medline] [Order article via Infotrieve]
  21. Tyagi, S. R., Neckelmann, N., Uhlinger, D. J., Burnham, D. N., and Lambeth, J. D. (1992) Biochemistry 31, 2765-2774 [Medline] [Order article via Infotrieve]
  22. Uhlinger, D. J., Inge, K. L., Kreck, M. L., Tyagi, S. R., Neckelmann, N., and Lambeth, J. D. (1992) Biochem. Biophys. Res. Commun. 186, 509-516 [Medline] [Order article via Infotrieve]
  23. Didsbury, J., Weber, R. F., Bokoch, G. M., Evans, T., and Snyderman, R. (1989) J. Biol. Chem. 264, 16378-16382 [Abstract/Free Full Text]
  24. Hiraoka, K., Kaibuchi, K., Ando, S., Musha, T., Takaishi, K., Mizuno, T., Asada, M., Menard, L., Tomhave, E., Didsbury, J., Snyderman, R., and Takai, Y. (1992) Biochem. Biophys. Res. Commun. 182, 921-930 [Medline] [Order article via Infotrieve]
  25. Abo, A., Pick, E., Hall, A., Totty, N., Teahan, C. G., and Segal, A. W. (1991) Nature 353, 668-670 [CrossRef][Medline] [Order article via Infotrieve]
  26. Kwong, C. H., Malech, H. L., Rotrosen, D., and Leto, T. L. (1993) Biochemistry 32, 5711-5717 [Medline] [Order article via Infotrieve]
  27. Chuang, T., Bohl, B. P., and Bokoch, G. M. (1993) J. Biol. Chem. 268, 26206-26211 [Abstract/Free Full Text]
  28. Quinn, M. T., Evans, T., Loetterle, L. R., Jesaitis, A. J., and Bokoch, G. M. (1993) J. Biol. Chem. 268, 20983-20987 [Abstract/Free Full Text]
  29. El Benna, J., Ruedi, J. M., and Babior, B. M. (1994) J. Biol. Chem. 269, 6729-6734 [Abstract/Free Full Text]
  30. Abo, A., Webb, M. R., Grogan, A., and Segal, A. (1994) Biochem. J. 298, 585-591 [Medline] [Order article via Infotrieve]
  31. Uhlinger, D. J., Tyagi, S. R., Inge, K. L., and Lambeth, J. D. (1993) J. Biol. Chem. 268, 8624-8631 [Abstract/Free Full Text]
  32. Le Cabec, V., Mohn, H., Gacon, G., and Maridonneau-Parini, I. (1994) Biochem. Biophys. Res. Commun. 198, 1216-1224 [CrossRef][Medline] [Order article via Infotrieve]
  33. Philips, M., Feoktistov, A., Pillinger, M., and Abramson, S. (1995) J. Biol. Chem. 270, 11514-11521 [Abstract/Free Full Text]
  34. Heyworth, P., Bohl, B., Bokoch, G., and Curnutte, J. (1994) J. Biol. Chem. 269, 30749-30752 [Abstract/Free Full Text]
  35. Dorseuil, O., Quinn, M. T., and Bokoch, G. M. (1995) J. Leukocyte Biol. 58, 108-113 [Abstract]
  36. Kleinberg, M. E., Malech, H. L., Mital, D. A., and Leto, T. L. (1994) Biochemistry 33, 2490-2495 [Medline] [Order article via Infotrieve]
  37. Dusi, S., Donini, M., and Rossi, F. (1996) Biochem. J. 314, 409-412 [Medline] [Order article via Infotrieve]
  38. Heyworth, P. G., Knaus, U. G., Xu, X., Uhlinger, D. J., Conroy, L., Bokoch, G. M., and Curnutte, J. T. (1993) Mol. Biol. Cell 4, 261-269 [Abstract]
  39. Escriou, V., LaPorte, F., Garin, J., Brandolin, G., and Vignais, P. (1994) J. Biol. Chem. 269, 14007-14014 [Abstract/Free Full Text]
  40. Ando, S., Kaibuchi, K., Sasaki, T., Hiraoka, K., Nishiyama, T., Mizuno, T., Asada, M., Nunoi, H., Matsuda, I., Matsuura, Y., Polakis, P., McCormick, F., and Takai, Y. (1992) J. Biol. Chem. 267, 25709-25713 [Abstract/Free Full Text]
  41. Kreck, M. L., Freeman, J. L., Abo, A., and Lambeth, J. D. (1996) Biochemistry 35, 15683-15692 [CrossRef][Medline] [Order article via Infotrieve]
  42. Marshall, M. S. (1993) Trends Biochem. Sci. 18, 250-254 [CrossRef][Medline] [Order article via Infotrieve]
  43. Warne, P. H., viciana, P. R., and Downward, J. (1993) Nature 364, 352-355 [CrossRef][Medline] [Order article via Infotrieve]
  44. Freeman, J. L. R., Kreck, M. L., Uhlinger, D. J., and Lambeth, J. D. (1994) Biochemistry 33, 13431-13435 [Medline] [Order article via Infotrieve]
  45. Xu, X., Barry, D., Settleman, J., Schwartz, M., and Bokoch, G. (1994) J. Biol. Chem. 269, 23569-23576 [Abstract/Free Full Text]
  46. Diekmann, D., Abo, A., Johnson, C., Segal, A., and Hall, A. (1994) Science 265, 531-533 [Medline] [Order article via Infotrieve]
  47. Freeman, J. L., Abo, A., and Lambeth, J. D. (1996) J. Biol. Chem. 271, 19794-19801 [Abstract/Free Full Text]
  48. Prigmore, E., Ahmed, S., Best, A., Kozma, R., Manser, E., Segal, A., and Lim, L. (1995) J. Biol. Chem. 270, 10717-10722 [Abstract/Free Full Text]
  49. Dorseuil, O., Reibel, L., Bokoch, G., Camonis, J., and Gacon, G. (1996) J. Biol. Chem. 271, 83-88 [Abstract/Free Full Text]
  50. Hirshberg, M., Stockley, R. W., Dodson, G., and Webb, M. R. (1997) Nat. Struct. Biol. 4, 147-152 [Medline] [Order article via Infotrieve]
  51. Hiratsuka, T. (1983) Biochim. Biophys. Acta 742, 496-508 [Medline] [Order article via Infotrieve]
  52. Kreck, M. L., Uhlinger, D. J., Tyagi, S. R., Inge, K. L., and Lambeth, J. D. (1994) J. Biol. Chem. 269, 4161-4168 [Abstract/Free Full Text]
  53. Pember, S. O., Barnes, K. C., Brandt, S. J., and Kinkade, J. M., Jr. (1983) Blood 61, 1105-1115 [Abstract]
  54. Burnham, D. N., Uhlinger, D. J., and Lambeth, J. D. (1990) J. Biol. Chem. 265, 17550-17559 [Abstract/Free Full Text]
  55. Lutter, R., van Schaik, M. L. J., van Zwieten, R., Wever, R., Roos, D., and Hamers, M. N. (1985) J. Biol. Chem. 260, 2237-2244 [Abstract]
  56. Rotrosen, D., Yeung, C. L., and Katkin, J. P. (1993) J. Biol. Chem. 268, 14256-14260 [Abstract/Free Full Text]
  57. Lambeth, J. D., Burnham, D. N., and Tyagi, S. R. (1988) J. Biol. Chem. 263, 3818-3822 [Abstract/Free Full Text]
  58. Nomanbhoy, T. K., and Cerione, R. A. (1996) J. Biol. Chem. 271, 10003-10009
  59. Uhlinger, D., Taylor, K., and Lambeth, J. D. (1994) J. Biol. Chem. 269, 22095-22098 [Abstract/Free Full Text]
  60. Diekmann, D., Nobes, C., Burbelo, P., Abo, A., and Hall, A. (1995) EMBO J. 14, 5297-5305 [Abstract]
  61. Deleted in proofDeleted in proof
  62. Deleted in proofDeleted in proof
  63. John, J., Sohment, R., Feurstein, J., Linke, R., Wittinghofer, A., and Goody, R. S. (1990) Biochemistry 29, 6058-6065 [Medline] [Order article via Infotrieve]
  64. Leonard, D. A., Evans, T., Hart, M., Cerione, R. A., and Manor, D. (1994) Biochemistry 33, 12323-12328 [Medline] [Order article via Infotrieve]
  65. Joseph, G., and Pick, E. (1995) J. Biol. Chem. 270, 29079-29082 [Abstract/Free Full Text]
  66. Kwong, C. H., Adams, A. G., and Leto, T. L. (1995) J. Biol. Chem. 270, 19868-19872 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.